Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension

US9494599B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
• Universite de Versailles Saint-Quentin-en-Yvelines · FR
• UNIVERSITE DE PARIS DESCARTES · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR

Inventors

• Pierre-Emmanuel Rautou · Paris, FR
• Chantal Boulanger · Paris, FR
• Dominique-Charles Valla · Paris, FR

Key dates

• Filing date: Jan 28, 2013
• Grant date: Nov 15, 2016
• Expiry date: Jan 28, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/085
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41−), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.